Venus Remedies Gets Approval To Market Cancer Drugs In Serbia

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Venus Remedies gets approval to market cancer drugs in Serbia

ri-calendar-2-lineSep 20, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Venus Remedies, a pharmaceutical company, received marketing approval from Serbia for its cancer-treatment medications.

 

"The company has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs beneficial in the treatment of various types of cancer. With this, Venus Remedies has now secured a total of 511 marketing approvals for its oncology products across 66 countries," the company said in a regulatory filing with the exchanges.

 

"We have more than 40 marketing authorisations in South Eastern Europe and Balkan region, including nine for oncology drugs. The marketing authorisation from Serbia is a significant milestone that will help improve access to affordable cancer drugs in the region," said Aditi Chaudhary, president of international business at Venus Remedies.

 

Venus Remedies is a pharmaceutical manufacturing company. The company specializes in producing various formulations in the therapeutic segment such as antibiotics, oncology drugs, and critical care medicines.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartCommodities

Why Gold Remains a Safe Haven Amid Global Economic Shifts in 2025

0 people read

4 mins read . Sep 5, 2025

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions